{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:20:26Z","timestamp":1793431226631,"version":"4.5.0"},"reference-count":64,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nowadays, minimal residual disease (MRD) is accepted as the strongest independent prognostic factor in acute lymphoblastic leukemia (ALL). It can be detected by molecular methods that use leukemia-specific or patient-specific molecular markers (fusion gene transcripts, or immunoglobulin\/T-cell receptor [IG\/TR] gene rearrangements), and by multi-parametric flow cytometry. The sensitivity and specificity of these methods can vary across treatment time points and therapeutic settings. Thus, knowledge of the principles and limitations of each technology is of the utmost importance for correct interpretation of MRD results. Time will tell whether new molecular and flow cytometric high-throughput technologies can overcome the limitations of current standard methods and eventually bring additional benefits. MRD during standard ALL chemotherapy is the strongest overall prognostic indicator and has therefore been used for refining initial treatment stratification. Moreover, MRD positivity after the maintenance phase of treatment may point to an impending relapse and thus enable salvage treatment to be initiated earlier, which could possibly improve treatment results. The prognostic relevance of pretransplantation MRD was shown by several studies, and MRD high-risk patients were shown to benefit from stem cell transplantation (SCT). Also, MRD positivity after SCT correlates with worse outcomes. In addition, MRD information is very instructive in current clinical trials that test novel agents to evaluate their treatment efficacy. Although conventional clinical risk factors lose their independent prognostic significance when combined with MRD information, recently identified genetic markers may further improve the treatment stratification in ALL.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.13","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:11Z","timestamp":1555452791000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation"],"prefix":"10.1182","volume":"2017","author":[{"given":"Monika","family":"Br\u00fcggemann","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kotrova","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111704241836500_B1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111704241836500_B2","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111704241836500_B3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/bmt.2017.16","article-title":"Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL","volume":"52","author":"Kotrova","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111704241836500_B4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/bmt.2008.122","article-title":"B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL","volume":"42","author":"Fronkova","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111704241836500_B5","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2011.060426","article-title":"Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"97","author":"Gaipa","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2019111704241836500_B6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/leu.2012.231","article-title":"Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"27","author":"Denys","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2019111704241836500_B7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2015-07-655159","article-title":"The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL","volume":"126","author":"Kotrova","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111704241836500_B8","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/bmt.2016.305","article-title":"GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses","volume":"52","author":"Sellner","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111704241836500_B9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2019111704241836500_B10","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111704241836500_B11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111704241836500_B12","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.leu.2402636","article-title":"Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"issue":"7","key":"2019111704241836500_B13","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","article-title":"Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"issue":"26","key":"2019111704241836500_B14","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111704241836500_B15","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111704241836500_B16","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2019111704241836500_B17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"key":"2019111704241836500_B18","article-title":"Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy [published online ahead of print 21 August 2017]","author":"Nagel","journal-title":"Blood"},{"issue":"1","key":"2019111704241836500_B19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.seminoncol.2011.11.009","article-title":"Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle","volume":"39","author":"Br\u00fcggemann","year":"2012","journal-title":"Semin Oncol"},{"issue":"9","key":"2019111704241836500_B20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111704241836500_B21","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2019111704241836500_B22","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2019111704241836500_B23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111704241836500_B24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"GRAALL group. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111704241836500_B25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/bjh.13834","article-title":"Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia","volume":"172","author":"Ravandi","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111704241836500_B26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ejh.12587","article-title":"Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia","volume":"96","author":"\u0160\u00e1lek","year":"2016","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111704241836500_B27","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"issue":"31","key":"2019111704241836500_B28","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111704241836500_B29","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1002\/cncr.30262","article-title":"Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"122","author":"Short","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"2019111704241836500_B30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","article-title":"The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Zhou","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2019111704241836500_B31","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/bcj.2014.48","article-title":"Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia","volume":"4","author":"Bassan","year":"2014","journal-title":"Blood Cancer J"},{"issue":"10","key":"2019111704241836500_B32","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bbmt.2014.05.026","article-title":"Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia","volume":"20","author":"Terwey","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111704241836500_B33","author":"Bar","year":"2014"},{"issue":"2","key":"2019111704241836500_B34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00277-011-1285-1","article-title":"Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Zhao","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111704241836500_B35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"issue":"11","key":"2019111704241836500_B36","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"36","key":"2019111704241836500_B37","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111704241836500_B38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111704241836500_B39","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111704241836500_B40","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"issue":"9967","key":"2019111704241836500_B41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2019111704241836500_B42","author":"Davila","year":"2014"},{"issue":"25","key":"2019111704241836500_B43","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111704241836500_B44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111704241836500_B45","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"2019111704241836500_B46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cncr.30264","article-title":"Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"2019111704241836500_B47","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3324\/haematol.2015.127837","article-title":"Personalized medicine in adult acute lymphoblastic leukemia","volume":"100","author":"Hoelzer","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"2019111704241836500_B48","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.bbmt.2016.07.021","article-title":"Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome","volume":"22","author":"Lussana","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111704241836500_B49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2015.217","article-title":"Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT","volume":"51","author":"Nishiwaki","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111704241836500_B50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","article-title":"Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study","volume":"19","author":"Tanguy-Schmidt","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2019111704241836500_B51","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111704241836500_B52","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111704241836500_B53","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111704241836500_B54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis","volume":"102","author":"Herold","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"2019111704241836500_B55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111704241836500_B56","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111704241836500_B57","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1\u2013like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111704241836500_B58","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","article-title":"Has MRD monitoring superseded other prognostic factors in adult ALL?","volume":"120","author":"Br\u00fcggemann","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111704241836500_B59","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111704241836500_B60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ajh.24629","article-title":"Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission","volume":"92","author":"Pemmaraju","year":"2017","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111704241836500_B61","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111704241836500_B62","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111704241836500_B63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.680.680","article-title":"Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL) [abstract]","volume":"126","author":"G\u00f6kbuget","year":"2015","journal-title":"Blood"},{"issue":"9757","key":"2019111704241836500_B64","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/13\/1249687\/hem00002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/13\/1249687\/hem00002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:24:37Z","timestamp":1573982677000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/13\/21072\/Minimal-residual-disease-in-adult-ALL-technical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.13","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}